(Q50788257)

English

The efficacy and safety of standardized allergen-removed Rhus verniciflua extract as maintenance therapy after first-line chemotherapy in patients with advanced non-small cell lung cancer.

scientific article published in January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23895151

The efficacy and safety of standardized allergen-removed Rhus verniciflua extract as maintenance therapy after first-line chemotherapy in patients with advanced non-small cell lung cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23895151

1 reference

based on heuristic

inferred from title

Rhus verniciflua

object named as

Rhus verniciflua

1 reference

based on heuristic

inferred from title

author name string

Jinsoo Lee

1

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23895151

Jean Chae

2

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23895151

Sookyung Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23895151

Kyungsuk Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23895151

Wankyu Eo

5

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23895151

Sehyun Kim

6

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23895151

Woncheol Choi

7

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23895151

Seong Ha Cheon

8

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23895151

publication date

1 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23895151

The American Journal of Chinese Medicine

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23895151

41

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23895151

4

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23895151

773-787

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23895151

Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study.

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Efficacy and safety of Rhus verniciflua stokes extracts in patients with previously treated advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Rhus verniciflua stokes against advanced cancer: a perspective from the Korean Integrative Cancer Center

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Continuing trastuzumab beyond progression.

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Flavonoids purified from Rhus verniciflua Stokes actively inhibit cell growth and induce apoptosis in human osteosarcoma cells

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Inhibition of the PI3K-Akt/PKB survival pathway enhanced an ethanol extract of Rhus verniciflua Stokes-induced apoptosis via a mitochondrial pathway in AGS gastric cancer cell lines

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Selective cytotoxic effects on human cancer cell lines of phenolic-rich ethyl-acetate fraction from Rhus verniciflua Stokes.

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Ethanol-eluted extract of Rhus verniciflua stokes inhibits cell growth and induces apoptosis in human lymphoma cells

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua Stokes extract.

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weekly paclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

An outbreak of contact dermatitis from Rhus verniciflua (Toxicodendron vernicifluum).

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, r

1 reference

https://api.crossref.org/works/10.1142%2FS0192415X13500523

21 January 2018

Identifiers

10.1142/S0192415X13500523

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23895151

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 March 2018

http://europepmc.org/abstract/MED/23895151

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50788257&oldid=1766512756"